Addressing Bulky Lesions with Isatuximab Quadruplet Induction Myeloma Therapy

A recent clinical report highlights the remarkable efficacy of isatuximab quadruplet induction myeloma therapy in a 77-year-old woman. She presented with newly diagnosed immunoglobulin (Ig)G-κ multiple myeloma and a massive cranial paraskeletal lesion. This lesion, measuring 84 × 59 × 62 mm, significantly compressed her occipital lobe. Cytogenetic analysis through fluorescence in situ hybridization (FISH) revealed high-risk features, specifically 1q21 gain and 17p deletion.

Consequently, the medical team initiated induction therapy using isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd). This aggressive approach successfully avoided the need for emergent local surgical or radiation intervention. The clinical response occurred with striking speed. By day 28, head computed tomography showed an 80% reduction in the lesion's bidimensional measurements. Furthermore, near-complete radiologic resolution was achieved by the end of the second cycle.

Clinical Significance of Isa-VRd in High-Risk Myeloma

The patient eventually underwent elective reconstructive cranioplasty after three cycles of isatuximab quadruplet induction myeloma treatment. Although a pretreatment biopsy was not possible, the resected tissue contained no detectable plasma cells. Moreover, measurable residual disease (MRD) in the bone marrow turned negative. This case underscores the potency of quadruplet regimens in managing extramedullary disease (EMD).

Traditionally, patients with 17p deletions and 1q21 gains face a poor prognosis. However, the addition of isatuximab to the VRd backbone significantly enhances deep responses. According to the IMROZ trial, Isa-VRd reduces the risk of progression or death by approximately 40% in transplant-ineligible patients. This case demonstrates that even bulky, life-threatening paraskeletal lesions can regress rapidly without immediate neurosurgery.

Conclusion

In summary, the use of quadruplet induction regimens represents a major advancement for high-risk patients. Clinicians should consider this combination early, especially when facing bulky extramedullary involvement where rapid debulking is critical for preserving organ function.

Frequently Asked Questions

What makes Isa-VRd effective for extramedullary lesions?

Isatuximab is a monoclonal antibody targeting CD38, which induces myeloma cell death through multiple pathways. When combined with proteasome inhibitors and immunomodulatory drugs, it provides synergistic activity that can penetrate paraskeletal and extramedullary tissues more effectively than standard triplet therapy.

How do 1q21 gain and 17p deletion affect treatment choice?

These cytogenetic abnormalities signify high-risk disease, which often resists standard triplet therapies. Quadruplet induction is now recommended for such patients to achieve deeper, more durable responses and higher rates of MRD negativity.

Is surgical intervention always necessary for cranial lesions in myeloma?

As shown in this case, rapid response to systemic induction can sometimes resolve bulky lesions. This approach can turn emergent surgeries into elective reconstructive procedures once the systemic disease is under control.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. Refer to the latest local and national guidelines for clinical practice.

References

1. Ito S et al. Rapid regression of a bulky cranial lesion in high-risk multiple myeloma with isatuximab-based quadruplet induction. Int J Hematol. 2026 Apr 26. doi: 10.1007/s12185-026-04216-z. PMID: 42035382.


2. Facon T et al. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Transplant-Ineligible Multiple Myeloma. N Engl J Med. 2024. doi: 10.1056/NEJMoa2400347.


3. FDA. FDA approves isatuximab-irfc with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma. September 20, 2024.